Glehen Olivier, Mohamed Faheez, Sugarbaker Paul H
Surgical Department, Centre Hospitalo-Universitaire Lyon Sud, Pierre Bénite, France.
Ann Surg. 2004 Aug;240(2):278-85. doi: 10.1097/01.sla.0000133183.15705.71.
The aim of this study was to analyze the survival of patients with peritoneal dissemination of appendiceal malignancy having incomplete cytoreductive surgery.
Cytoreductive surgery plus perioperative intraperitoneal chemotherapy has emerged as a new and potentially curative treatment option for patients with peritoneal dissemination of appendiceal mucinous tumors. The goal of surgery is to remove all visible disease. Nevertheless, in some patients, complete cytoreduction is not possible.
Over a 30-year period, 645 patients with epithelial peritoneal surface malignancy of appendiceal origin were treated with cytoreductive surgery and intraperitoneal chemotherapy by a single surgeon. One hundred seventy-four (27.1%) of these patients had an incomplete cytoreduction. A critical statistical analysis of the impact of selected clinical features on survival was performed from a prospective database.
Mortality and morbidity rates were 0% and 33.3%, respectively. Median survival of these 174 patients was 20.5 months and their 1-year, 3-year, and 5-year survival rates were 71%, 34%, and 15%, respectively. By multivariate analysis, the presence of signet ring cells and lymph node involvement were independent prognostic indicators of poor survival (P = 0.047 and P < 0.001, respectively). Patients who underwent more than 1 cytoreduction or repeat intraperitoneal chemohyperthermia showed significant improvement in survival (P = 0.018 and P < 0.001, respectively)
Incomplete cytoreduction plus perioperative intraperitoneal chemotherapy of peritoneal dissemination from appendiceal malignancy results in limited long-term survival. Patients with signet ring histology or lymph node involvement have an especially poor outcome. Repeat cytoreduction and intraperitoneal chemohyperthermia may improve outcome.
本研究旨在分析接受不完全肿瘤细胞减灭术的阑尾恶性肿瘤腹膜播散患者的生存率。
肿瘤细胞减灭术联合围手术期腹腔内化疗已成为阑尾黏液性肿瘤腹膜播散患者一种新的、有潜在治愈可能的治疗选择。手术的目标是切除所有可见病灶。然而,在一些患者中,无法实现完全肿瘤细胞减灭。
在30年期间,由一名外科医生对645例阑尾来源的上皮性腹膜表面恶性肿瘤患者进行了肿瘤细胞减灭术和腹腔内化疗。其中174例(27.1%)患者肿瘤细胞减灭不完全。从一个前瞻性数据库对选定临床特征对生存的影响进行了关键的统计分析。
死亡率和发病率分别为0%和33.3%。这174例患者的中位生存期为20.5个月,其1年、3年和5年生存率分别为71%、34%和15%。多因素分析显示,印戒细胞的存在和淋巴结受累是生存不良的独立预后指标(分别为P = 0.047和P < 0.001)。接受超过1次肿瘤细胞减灭或重复腹腔内热化疗的患者生存率有显著提高(分别为P = 0.018和P < 0.001)。
阑尾恶性肿瘤腹膜播散的不完全肿瘤细胞减灭术联合围手术期腹腔内化疗导致长期生存有限。具有印戒细胞组织学特征或淋巴结受累的患者预后尤其差。重复肿瘤细胞减灭术和腹腔内热化疗可能改善预后。